Press Releases

Press Releases

Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

Nov 10, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical

Applied Molecular Transport to Present at Upcoming November Investor Conferences

Nov 08, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences: Event: Guggenheim 4 th Annual Immunology and Neurology Day

Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 07, 2022
Company held end of Phase 2 meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products Anticipate Phase 2 top-line readout for oral AMT-101 in UC monotherapy in late 2022 or early 2023, consistent with previous

Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Sep 20, 2022
Top-line data readout anticipated late 2022 or early 2023 SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD

Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 04, 2022
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved products Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development Announced top-line data for AMT-101 MARKET Phase 2 combination trial

Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Jul 06, 2022
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC)

Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Jul 05, 2022
Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2

Applied Molecular Transport to Present at Upcoming June Investor Conferences

Jun 02, 2022
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Event: Jefferies Global Healthcare Conference

Applied Molecular Transport Provides Strategy Update

May 18, 2022
Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with

Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 09, 2022
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022,

Displaying 1 - 10 of 19